



(11) **EP 1 755 637 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(51) Int Cl.:  
**A61K 38/10 (2006.01) A61P 19/08 (2006.01)**

(86) International application number:  
**PCT/AU2005/000638**

(48) Corrigendum issued on:  
**03.10.2012 Bulletin 2012/40**

(87) International publication number:  
**WO 2005/105132 (10.11.2005 Gazette 2005/45)**

(45) Date of publication and mention  
of the grant of the patent:  
**29.08.2012 Bulletin 2012/35**

(21) Application number: **05738284.8**

(22) Date of filing: **04.05.2005**

(54) **METHODS FOR PREVENTING OR TREATING BONE DISORDERS**

VERFAHREN ZUR PRÄVENTION ODER BEHANDLUNG VON KNOCHENERKRANKUNGEN  
METHODES DESTINEES A PREVENIR OU TRAITER DES MALADIES OSSEUSES

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR**

(30) Priority: **04.05.2004 AU 2004902388**

(43) Date of publication of application:  
**28.02.2007 Bulletin 2007/09**

(73) Proprietor: **Metabolic Pharmaceuticals Ltd.**  
**Port Melbourne, VIC 3207 (AU)**

(72) Inventor: **VOS, Evert**  
**Albuquerque, NM 87111 (US)**

(74) Representative: **Wright, Simon Mark**  
**J A Kemp**  
**14 South Square**  
**Gray's Inn**  
**London WC1R 5JJ (GB)**

(56) References cited:  
**WO-A1-01/33977 WO-A1-99/12969**  
**WO-A2-02/16589**

- **GUSTINA ANDREA ET AL: "Effects of Recombinant Human Growth Hormone (GH) on Bone and Intermediary Metabolism in Patients Receiving Chronic Glucocorticoid Treatment with Suppressed Endogenous GH Response to GH-Releasing Hormone" JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 80, no. 1, 1995, pages 122-129, XP009119355 ISSN: 0021-972X**
- **PAOLETTI A.M. ET AL: 'Efficacy and safety of oral and transdermal hormonal replacement treatment containing levonorgestrel.' MATURITAS. vol. 42, no. 2, 25 June 2002, pages 137 - 147, XP002266441**
- **NG F M ET AL: "Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats", JOURNAL OF MOLECULAR ENDOCRINOLOGY, vol. 25, no. 3, December 2000 (2000-12), pages 287-298, ISSN: 0952-5041**
- **'Growth Hormone (Somatotropin)', [Online] Retrieved from the Internet: <URL: www.vico.colostate.edu/hbooks/pathphys/endocrine/hypopit/gh.htm>**

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 1 755 637 B8**